Introduction
============

The rising morbidity and mortality of cancer has drawn extensive attention worldwide, and finding possible risk factors of tumorigenesis has been a priority task for researchers. Recently, an increasing number of studies have focused on associations between miRNA polymorphisms and cancer susceptibility, which indicated that accumulation of genetic variants may be involved in cancer development, including oral cancer,[@b1-ott-11-1121] lung cancer,[@b2-ott-11-1121],[@b3-ott-11-1121] gastric cancer,[@b4-ott-11-1121] breast cancer,[@b5-ott-11-1121] glioma,[@b6-ott-11-1121] non-small cell lung cancer,[@b7-ott-11-1121] hepatocellular carcinoma,[@b8-ott-11-1121],[@b9-ott-11-1121] gallbladder cancer,[@b10-ott-11-1121] and head and neck cancer (HNC).[@b11-ott-11-1121] As the molecular mechanism of cancer remains unclear, further exploration of more accurate cancer treatments and prognosis would be of great importance.

MiRNAs are a class of small non-coding RNAs with 18--25 nucleotides in length, which play as oncogenes or anti-oncogenes in the pathogenesis of tumor by targeting multiple genes.[@b12-ott-11-1121]--[@b14-ott-11-1121] Studies have shown that almost 10%--30% of all human gene expressions have been regulated by mature miRNAs.[@b15-ott-11-1121] MiRNAs could modulate related genes implicated in cellular processes, including cell differentiation, growth, apoptosis, and immune response.[@b16-ott-11-1121]--[@b18-ott-11-1121]

Hsa-microRNA-196a2 (miR-196a2), initially discovered by Lagos-Quintana et al,[@b19-ott-11-1121] has been proven to play important roles in various cancers.[@b20-ott-11-1121],[@b21-ott-11-1121] Single nucleotide polymorphisms (SNPs) provide new sources of genetic variation, which contribute to potential molecular mechanisms of cancer development.[@b22-ott-11-1121] SNPs or mutations in miRNA sequence may transform miRNA expression and/or maturation, related to miRNA function by activating the transcription of the primary transcript, pri-miRNA and pre-miRNA processing, and miRNA--mRNA interactions.[@b23-ott-11-1121] MiR-196a2 rs11614913, as a definitional miRNA polymorphism,[@b24-ott-11-1121]--[@b26-ott-11-1121] is crucially associated with cancer risk.[@b23-ott-11-1121],[@b27-ott-11-1121] It is located in the 3′-untranslated region of the miR-196a2 precursor.[@b28-ott-11-1121] Hoffman et al[@b5-ott-11-1121] also showed that miR-196a2 rs11614913 not only influenced the transcription level of mature miR-196a, but also had a biological effect on target gene production. This updated meta-analysis was performed to explore the association between the hsa-miR-196a2 polymorphism and cancer risk and to further estimate the overall cancer risk by pooling all available data.

Materials and methods
=====================

Publication search
------------------

Two investigators (LYH, HAB) carried out a systematic review on PubMed, Cochrane Library, and Web of Science, by using ("microRNA-196a2" or "miR-196a2", or "miR-196-a-2" or "miR-196-2" or "miR-196-a" or "rs11614913"), and ("cancer" or "tumor" or "carcinoma" or "neoplasm" or "malignancy"), and ("polymorphism" or "variation" or "susceptibility") as the search terms in order to identify potentially eligible studies. We based our dates for literature retrieval from January 2008 to September 2017.

Inclusion and exclusion criteria
--------------------------------

Relevant studies had to meet the following inclusion criteria: 1) full-text article; 2) evaluation of a link between miRNA polymorphisms and cancer risks; 3) sufficient data for estimating the odds ratio (OR) with 95% CI and a *P*-value. Studies containing two or more case-control groups were considered as two or more independent studies. Studies that were, 1) review, letters, and comment articles; 2) not for cancer risk; and 3) duplicate samples or publications, were excluded.

Assessment of study quality
---------------------------

The quality of the study was determined by the Newcastle--Ottawa Scale for cohort studies.

Data extraction
---------------

Data extraction from the eligible studies were performed independently by two authors (LYH, HAB), based on the inclusion and exclusion criteria. For each publication, the following data were recorded: first author, date of publication, country of origin, ethnicity, type of tumor, source of control groups, total numbers of cases and controls, and genotyping method.

Statistical analysis
--------------------

The departure of frequencies of miR-196a2 rs11614913 polymorphisms was assessed under the Hardy--Weinberg equilibrium (HWE) for each publication by adopting the goodness-of-fit test (chi-square or Fisher exact test). The association between the miR-196a2 rs11614913 polymorphisms and the risk of cancer was evaluated by calculating pooled OR together with corresponding 95% CI based on the method published by Woolf.[@b29-ott-11-1121] Also, a *P*-value\<0.05 was considered statistically significant. In addition, we used stratified meta-regression analyses to explore major causes of heterogeneity among the articles. We respectively examined the association between genetic mutants and cancer risk in allelic contrast (T vs C), homozygote comparisons (TT vs CC), heterozygote comparisons (TC vs CC), recessive model (TT vs TC+CC), and dominant model (TT+TC vs CC). Subgroup analyses were performed by ethnicity (Asian and Caucasian), tumor types (if one tumor type contained less than three individual studies, it was combined into "other cancer" subgroups), and source of control (hospital based and population based).

*Q* tests[@b30-ott-11-1121] and *I*^2^ tests[@b31-ott-11-1121] were carried out to test the heterogeneity. *I*^2^ values describe the percentage of total variation across studies that are due to heterogeneity rather than chance. *I*^2^=0% prompts no heterogeneity observed, with 25% identified as low, 50% as moderate, and 75% as high. If *I*^2^ was ≥50% or if the *P*-value of heterogeneity was \<0.05, indicating significant heterogeneity among these articles, a random-effect model was used;[@b32-ott-11-1121] otherwise, a fixed-effect mode was used.[@b33-ott-11-1121] Sensitivity analyses were conducted to estimate the stability of the meta-analysis result. We adopted Egger's test to assess potential publication bias by visual inspection of the Funnel plot. A *P*-value \<0.05 was regarded as an indication of potential publication bias.[@b34-ott-11-1121] All statistical analyses were performed with the Stata software package version 12.0 (Stata Corporation, College Station, TX, USA).

Results
=======

Study identification
--------------------

Overall, 84 articles,[@b1-ott-11-1121]--[@b11-ott-11-1121],[@b26-ott-11-1121],[@b27-ott-11-1121],[@b35-ott-11-1121]--[@b100-ott-11-1121] which were relevant to the search terms, were selected based on the inclusion criteria from PubMed, Cochrane, and Web of Science ([Figure 1](#f1-ott-11-1121){ref-type="fig"}). These studies with a total of 35,802 cases and 41,541 controls were subjected to further checking. In the present meta-analysis, we excluded 73 articles (36 articles were meta-analysis, 22 articles did not express concern about cancer risk, 11 articles lacked detailed allele frequency data or OR calculation, and four articles were incomplete text). The included study characteristics are provided in [Table 1](#t1-ott-11-1121){ref-type="table"}.

In total, there were studies on hepatocellular carcinoma (n=14), breast cancer (n=14), colorectal cancer (n=10), gastric cancer (n=10), lung cancer (n=9), esophageal squamous cell carcinoma (ESCC; n=6), HNC (n=5), bladder cancer (n=2), prostate cancer (n=2), oral squamous cell carcinoma (n=2), epithelial ovarian cancer (n=2), renal cell cancer (n=1), glioma (n=1), pancreatic cancer (n=1), cervical cancer (n=1), nasopharyngeal carcinoma (n=1), gallbladder cancer (n=1), acute lymphoblastic leukemia (n=1), and non-Hodgkin lymphoma (n=1). There were 64 studies of Asians and 18 studies of Caucasians.

Among the genotyping methods used in these studies, 57 studies used polymerase chain reaction (including polymerase chain reaction restriction fragment length polymorphism and polymerase chain reaction-ligation detection reaction), 16 studies used Taqman SNP genotyping assay, and others used MassARRAY and DNA sequencing. The controls of 42 studies mainly came from a hospital-based healthy population matched for gender and age, and 42 studies had population-based controls (PB). The distribution of genotypes in the controls of all of the studies was in agreement with HWE (*P*\>0.05).

Quantitative synthesis
----------------------

In this meta-analysis, we analyzed the hsa-miR-196a2 rs11614913 polymorphism in 84 comparisons with 35,802 cases and 41,541 controls. All the studies were pooled into the meta-analysis, and the results showed that the hsa-miR-196a2 rs11614913 polymorphism was significantly associated with the risk of cancer in the following genetic models: TT vs CC: OR =0.900, 95% CI =0.813--0.987, *P*=0.043; TT vs TC+CC: OR =0.918, 95% CI =0.851--0.989, *P*=0.025.

Then, we performed the subgroup analysis of different specific cancer types, genotypes, control sources, and ethnicities ([Table 2](#t2-ott-11-1121){ref-type="table"}). In the different cancer types, close association between rs11614913 and cancer risk was found for lung cancer (homozygote comparison, OR =0.840, 95% CI =0.734--0.961, *P*=0.011; recessive model, OR =0.858, 95% CI =0.771--0.955, *P*=0.005), hepatocellular carcinoma (allelic contrast, OR =0.894, 95% CI =0.800--0.998, *P*=0.047; homozygote comparison, OR =0.900, 95% CI =0.813--0.997, *P*=0.039; recessive model, OR =0.800, 95% CI =0.678--0.944, *P*=0.008), and HNC (allelic contrast, OR =1.076, 95% CI =1.006--1.152, *P*=0.033; homozygote comparison, OR =1.214, 95% CI =1.043--1.413, *P*=0.012; [Figures 2](#f2-ott-11-1121){ref-type="fig"} and [3](#f3-ott-11-1121){ref-type="fig"}). However, the association between rs11614913 and breast cancer, ESCC, gastric cancer (GC), or colorectal cancer (CRC) is not statistically significant.

In ethnic subgroup analysis, a strong association was found between rs11614913 and cancer risk in the allelic contrast (T vs C: OR =0.847, 95% CI =0.899--0.997, *P*=0.038), the homozygote comparison (TT vs CC: OR =0.878, 95% CI =0.788--0.977, *P*=0.017), and the recessive model (OR =0.895, 95% CI =0.824--0.972, *P*=0.008) among Asians, whereas negative results were obtained for Caucasians in all genetic models. Additionally, decreased risk was observed in the polymerase chain reaction (PCR) method for the homozygote comparison (TT vs CC: OR =0.849, 95% CI =0.732--0.986, *P*=0.032) and the recessive model (TT vs TC+CC: OR =0.880, 95% CI =0.800--0.969, *P*=0.009), and no significant association of cancer risk was found in Taqman and other methods.

Test of heterogeneity
---------------------

Among the studies of rs11614913, we found heterogeneity in overall comparisons and subgroup analysis. Moreover, the heterogeneity we evaluated for all genetic models by ethnicity, cancer type, source of controls, as well HWE status was significant. However, we found that heterogeneity could not be explained by the variable ethnicity, cancer type, source of controls, and HWE status (data not shown).

Sensitivity analysis
--------------------

Sensitivity analysis was conducted to assess the effect by excluding a single study in turn. Sensitivity analysis of the rs11614913 polymorphism in an allelic comparison is presented in [Table S1](#SD1-ott-11-1121){ref-type="supplementary-material"}. Overall, we found that no individual study had an influence on the pooled OR. The results demonstrated that the pooled ORs were not materially altered, suggesting the stability of our meta-analysis.

Publication bias
----------------

The publication bias of the present meta-analysis was assessed by Begg's funnel plot and Egger's test. The funnel plot for the rs11614913 polymorphism in the allelic comparison is presented in [Table S2](#SD2-ott-11-1121){ref-type="supplementary-material"}. No evidence of publication bias was noted in Begg's funnel plot (T vs C \[*P*-value for Begg's test =0.660\], TT vs CC \[*P*-value for Begg's test =0.971, [Figure 4](#f4-ott-11-1121){ref-type="fig"}\], TC vs CC \[*P*-value for Begg's test =0.951\], TT vs TC+CC \[*P*-value for Begg's test =0.908, [Figure 4](#f4-ott-11-1121){ref-type="fig"}\], TC+TT vs CC \[*P*-value for Begg's test =0.592\]) and Egger's test (allele contrast \[*P*=0.923\], homozygous model \[*P*=0.822\], heterozygous model \[*P*=0.761\], recessive model \[*P*=0.899\], and dominant model \[*P*=0.401\]). The quality of included studies is presented in [Table 3](#t3-ott-11-1121){ref-type="table"}.

Discussion
==========

MiRNAs are reported as critical posttranscriptional regulators in gene expression and are involved in various diseases. The associations between miR-196a2 rs11614913 polymorphism and susceptibility to different cancers are widely explored. Guo et al[@b101-ott-11-1121] found that the C allele had the effect of increasing cancer risk in gastric cancer, and Ma et al[@b102-ott-11-1121] found that TT could decrease the risk of colorectal cancer. Moreover, Wang et al[@b103-ott-11-1121] and Zhang et al[@b104-ott-11-1121] showed that the rs11614913 polymorphism has no association with the risk of hepatocellular carcinoma. However, the regulatory effects of miRNA in carcinogenesis remain unclear. Therefore, we performed this updated meta-analysis to explore the molecular mechanisms of the genetic associations between miRNA and SNPs with cancer risk.

MiR-196a2 is composed of two distinct mature miRNAs (miR-196a-3P and miR-196a-5P), which are processed from the same stem loop;[@b105-ott-11-1121] thus, the potential targets of miR-196a could be influenced by its altered expression patterns. SNPs in miRNAs could potentially affect the processing or target selection of miRNAs,[@b106-ott-11-1121],[@b107-ott-11-1121] which is identified as a key factor in oncogenesis, and contributes to regulate the translation or degradation of messenger RNA (mRNA).[@b23-ott-11-1121] Hoffman et al[@b5-ott-11-1121] found that the expression of mature miR-196a2 was increased 9.3-fold in cells transfected with pre-miR-196a2-C but upregulated only by 4.4-fold with pre-miR-196a2-T, and that the C allele of rs11614913 increased mature miR-196a2 levels in lung cancer[@b7-ott-11-1121] and CRC[@b42-ott-11-1121] tissues. Xu et al[@b108-ott-11-1121] have shown that miR-196a2 rs11614913 CC is associated with significantly increased expression of mature miR-196a (lower cycle threshold corresponding to a higher expression) in cardiac tissue specimens of congenital heart disease, and the increased miR-196a expression could further decrease mRNA target of HOXB8. These results indicated that the rs11614913 polymorphism may affect the processing of the pre-miRNA to its mature form.

Several meta-analyses have been performed to analyse the SNP of this miRNA that is associated with the cancer risk.[@b104-ott-11-1121],[@b109-ott-11-1121] In our present work, we screened out all the studies published to date and included more papers and cancer types than the previously published meta-analyses. For example, Kang et al[@b109-ott-11-1121] conducted a meta-analysis encompassing the rs11614913 polymorphism in miR-196a2 and cancer risks, which suggested that the rs11614913 polymorphism may contribute to decreased susceptibility to liver cancer (allele model, homozygous model, dominant model, and heterozygous model) and lung cancer (allele model, homozygous model, and recessive model); however, this was not duplicated in our meta-analysis. In this study, we concluded that the rs11614913 polymorphism conferred a decreased susceptibility to lung cancer (homozygote comparison, recessive model) and hepatocellular carcinoma (allelic contrast, homozygote comparison, recessive model) or an increased susceptibility to HNC (allelic contrast, homozygote comparison). Our study had a larger sample size than the previous ones, which might influence the results. In addition, the previous meta-analyses did not evaluate the quality of the included studies.

According to the procedure of seeking for the source of heterogeneity, we performed subgroup studies according to cancer type, ethnicity, and source of control. A strong association was found between rs11614913 and cancer risk in lung cancers, hepatocellular carcinoma, and HNC, but not in breast cancer, gastric cancer, ESCC, or CRC, which was not similar to the findings of previous studies.[@b101-ott-11-1121]--[@b103-ott-11-1121],[@b109-ott-11-1121] The present meta-analysis showed that homozygote TT had the effect of decreasing the risk of lung cancer or hepatocellular carcinoma compared with that of CC homozygote or C allele carriers. We conducted another subgroup analysis by population to determine the association between these miRNA polymorphisms and tumorigenesis. The results suggested that individuals with alterative T allele could decrease cancer susceptibility in Asians but not in Caucasians, indicating that the difference of ethnic background and the living environment may also be a risk factor.

To determine the hsa-miR-196a2 rs11614913 polymorphism, PCR, Taqman, and other methods have been adopted. We found that the hsa-miR-196a2 rs11614913 polymorphism significantly decreased cancer risk in homozygous models and the recessive model when using the PCR method, but this result was not shown when selecting Taqman and other methods. Therefore, more effort may be necessary for further progress in SNP analysis. We found sources of heterogeneity in the studies from cancer type and ethnicity suggesting cancer and population playing important roles. When detecting the source of control, we observed significant associations in population-based and hospital-based controls. This may be due to the included studies matching age, gender, and residential area to control selection bias.

Nevertheless, several defects of this meta-analysis should be emphasized. Firstly, although we strictly screened articles and precisely extracted the data, the differences in the selection of subjects could not be eliminated. Secondly, in our meta-analysis, only Asian and Caucasian ethnicities were included, and the impact of the differences in racial descent should not be ignored. Thirdly, potential language bias could not be avoided due to limitation of studies published in English or Chinese. Therefore, it is not possible to avoid potential publication bias in this meta-analysis.

In summary, miR-196a2 rs11614913 polymorphism may contribute to the development of cancer, especially in lung cancer, hepatocellular carcinoma, and HNC. It might be useful as a candidate marker for the diagnosis of these cancers, and could also be a potential protective factor for cancer risks in Asians. Furthermore, more significant studies and investigations with larger populations focusing on cancer types or ethnicities should be performed to confirm the results.

Supplementary materials
=======================

###### 

Details of the sensitivity analyses of the association between rs11614913 polymorphism and cancer risk homozygous model (TT vs CC) and recessive model (TT vs TC+CC).

  Comparison                                                                                                                          Study omitted                 Estimate   (95% Conf Interval)   
  ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------- ---------- --------------------- -------
  TT vs CC                                                                                                                            Hu et al[@b122-ott-11-1121]   0.902      0.814                 0.999
  Hu et al[@b150-ott-11-1121]                                                                                                         0.904                         0.815      1.002                 
  Tian et al[@b118-ott-11-1121]                                                                                                       0.902                         0.814      1.001                 
  Hoffman et al[@b120-ott-11-1121]                                                                                                    0.890                         0.805      0.985                 
  Catucci et al[@b151-ott-11-1121]                                                                                                    0.900                         0.811      1.000                 
  Wang et al[@b153-ott-11-1121]                                                                                                       0.911                         0.824      1.008                 
  Okubo et al[@b198-ott-11-1121]                                                                                                      0.900                         0.812      0.998                 
  Peng et al[@b119-ott-11-1121]                                                                                                       0.904                         0.816      1.002                 
  Srivastava et al[@b125-ott-11-1121]                                                                                                 0.903                         0.815      1.000                 
  Dou et al[@b121-ott-11-1121]                                                                                                        0.897                         0.809      0.994                 
  Li et al[@b124-ott-11-1121]                                                                                                         0.906                         0.818      1.003                 
  Akkiz et al[@b123-ott-11-1121]                                                                                                      0.908                         0.820      1.005                 
  Liu et al[@b126-ott-11-1121]                                                                                                        0.898                         0.810      0.997                 
  Kim et al[@b216-ott-11-1121]                                                                                                        0.904                         0.815      1.002                 
  Catucci et al[@b151-ott-11-1121]                                                                                                    0.899                         0.810      0.997                 
  Christensen et al[@b152-ott-11-1121]                                                                                                0.900                         0.813      0.997                 
  Mittal et al[@b156-ott-11-1121]                                                                                                     0.904                         0.816      1.001                 
  Jedlinski et al[@b155-ott-11-1121]                                                                                                  0.900                         0.813      0.998                 
  Zhan et al[@b157-ott-11-1121]                                                                                                       0.906                         0.818      1.004                 
  Zhou et al[@b158-ott-11-1121]                                                                                                       0.901                         0.813      0.998                 
  Vinci et al[@b217-ott-11-1121]                                                                                                      0.895                         0.809      0.992                 
  Hong et al[@b117-ott-11-1121]                                                                                                       0.902                         0.814      1.000                 
  George et al[@b154-ott-11-1121]                                                                                                     0.902                         0.815      0.999                 
  Linhares et al[@b160-ott-11-1121]                                                                                                   0.893                         0.806      0.988                 
  Chen et al[@b159-ott-11-1121]                                                                                                       0.898                         0.811      0.995                 
  Min et al[@b139-ott-11-1121]                                                                                                        0.904                         0.815      1.002                 
  Zhu et al[@b162-ott-11-1121]                                                                                                        0.905                         0.816      1.003                 
  Hezova et al[@b140-ott-11-1121]                                                                                                     0.897                         0.810      0.994                 
  Zhang et al[@b215-ott-11-1121]                                                                                                      0.900                         0.812      0.998                 
  Yoon et al[@b161-ott-11-1121]                                                                                                       0.904                         0.816      1.001                 
  Zhang et al[@b214-ott-11-1121]                                                                                                      0.904                         0.816      1.001                 
  Chu et al[@b202-ott-11-1121]                                                                                                        0.894                         0.807      0.990                 
  Vinci et al[@b220-ott-11-1121]                                                                                                      0.897                         0.810      0.994                 
  Ahn et al[@b218-ott-11-1121]                                                                                                        0.902                         0.814      1.000                 
  Lv et al[@b166-ott-11-1121]                                                                                                         0.878                         0.798      0.965                 
  Umar et al[@b219-ott-11-1121]                                                                                                       0.895                         0.808      0.992                 
  Wei et al[@b221-ott-11-1121]                                                                                                        0.896                         0.809      0.993                 
  Wang et al[@b168-ott-11-1121]                                                                                                       0.894                         0.807      0.990                 
  Zhang et al[@b170-ott-11-1121]                                                                                                      0.904                         0.816      1.003                 
  Han et al[@b164-ott-11-1121]                                                                                                        0.898                         0.810      0.996                 
  Pavlakis et al[@b208-ott-11-1121]                                                                                                   0.899                         0.812      0.996                 
  Tong et al[@b180-ott-11-1121]                                                                                                       0.901                         0.813      1.000                 
  Pu et al[@b199-ott-11-1121]                                                                                                         0.902                         0.814      1.000                 
  Bansal et al[@b171-ott-11-1121]                                                                                                     0.902                         0.815      1.000                 
  Kupcinskas et al[@b177-ott-11-1121]                                                                                                 0.897                         0.809      0.994                 
  Qu et al[@b179-ott-11-1121]                                                                                                         0.905                         0.817      1.003                 
  Wang et al[@b181-ott-11-1121]                                                                                                       0.897                         0.809      0.994                 
  Dikeakos et al[@b173-ott-11-1121]                                                                                                   0.925                         0.843      1.015                 
  Qi et al[@b201-ott-11-1121]                                                                                                         0.902                         0.814      1.000                 
  Chu et al[@b172-ott-11-1121]                                                                                                        0.898                         0.810      0.995                 
  Parlayan et al[@b222-ott-11-1121]                                                                                                   0.900                         0.812      0.997                 
  Li et al[@b178-ott-11-1121]                                                                                                         0.896                         0.808      0.993                 
  Du et al[@b174-ott-11-1121]                                                                                                         0.892                         0.806      0.987                 
  Omrani et al[@b200-ott-11-1121]                                                                                                     0.900                         0.813      0.997                 
  Kou et al[@b206-ott-11-1121]                                                                                                        0.907                         0.819      1.004                 
  Roy et al[@b209-ott-11-1121]                                                                                                        0.896                         0.809      0.993                 
  Li et al[@b178-ott-11-1121]                                                                                                         0.896                         0.808      0.993                 
  Deng et al[@b182-ott-11-1121]                                                                                                       0.900                         0.812      0.997                 
  Qi et al[@b187-ott-11-1121]                                                                                                         0.907                         0.819      1.005                 
  Dikaiakos et al[@b183-ott-11-1121]                                                                                                  0.899                         0.812      0.996                 
  Li et al[@b184-ott-11-1121]                                                                                                         0.890                         0.805      0.985                 
  Li et al[@b184-ott-11-1121]                                                                                                         0.907                         0.819      1.004                 
  Nikolic et al[@b186-ott-11-1121]                                                                                                    0.902                         0.814      1.000                 
  He et al[@b205-ott-11-1121]                                                                                                         0.901                         0.813      0.999                 
  Sushma et al[@b212-ott-11-1121]                                                                                                     0.909                         0.821      1.006                 
  Sodhi et al[@b210-ott-11-1121]                                                                                                      0.891                         0.806      0.986                 
  Jiang et al[@b141-ott-11-1121]                                                                                                      0.896                         0.808      0.993                 
  Toraih et al[@b213-ott-11-1121]                                                                                                     0.894                         0.807      0.990                 
  Dai et al[@b189-ott-11-1121]                                                                                                        0.908                         0.820      1.005                 
  Zhao et al[@b197-ott-11-1121]                                                                                                       0.898                         0.811      0.995                 
  Song et al[@b194-ott-11-1121]                                                                                                       0.907                         0.819      1.004                 
  Shen et al[@b193-ott-11-1121]                                                                                                       0.902                         0.813      1.002                 
  Li et al[@b190-ott-11-1121]                                                                                                         0.907                         0.820      1.005                 
  Li et al[@b191-ott-11-1121]                                                                                                         0.906                         0.819      1.004                 
  Xu et al[@b195-ott-11-1121]                                                                                                         0.906                         0.818      1.004                 
  Qiu et al[@b192-ott-11-1121]                                                                                                        0.905                         0.817      1.003                 
  Jiang et al[@b141-ott-11-1121]                                                                                                      0.901                         0.813      1.000                 
  Yin et al[@b196-ott-11-1121]                                                                                                        0.901                         0.813      0.999                 
  Zhang et al[@b214-ott-11-1121]                                                                                                      0.901                         0.813      0.998                 
  Sun et al[@b211-ott-11-1121]                                                                                                        0.904                         0.817      1.002                 
  Toraih et al[@b213-ott-11-1121]                                                                                                     0.894                         0.808      0.990                 
  Morales et al[@b207-ott-11-1121]                                                                                                    0.901                         0.812      0.999                 
  Gu et al[@b203-ott-11-1121]                                                                                                         0.891                         0.805      0.986                 
  Hashemi et al[@b204-ott-11-1121]                                                                                                    0.896                         0.809      0.992                 
  Combined[@b117-ott-11-1121]--[@b125-ott-11-1121],[@b140-ott-11-1121],[@b141-ott-11-1121],[@b150-ott-11-1121]--[@b222-ott-11-1121]   0.900                         0.813      0.997                 
  TT vs TC+CC                                                                                                                         Hu et al[@b122-ott-11-1121]   0.918      0.851                 0.991
  Hu et al[@b150-ott-11-1121]                                                                                                         0.920                         0.852      0.993                 
  Tian et al[@b118-ott-11-1121]                                                                                                       0.918                         0.850      0.991                 
  Hoffman et al[@b120-ott-11-1121]                                                                                                    0.910                         0.844      0.980                 
  Catucci et al[@b151-ott-11-1121]                                                                                                    0.917                         0.849      0.991                 
  Wang et al[@b153-ott-11-1121]                                                                                                       0.928                         0.862      0.999                 
  Okubo et al[@b198-ott-11-1121]                                                                                                      0.917                         0.850      0.991                 
  Peng et al[@b119-ott-11-1121]                                                                                                       0.919                         0.852      0.991                 
  Srivastava et al[@b125-ott-11-1121]                                                                                                 0.918                         0.850      0.990                 
  Dou et al[@b121-ott-11-1121]                                                                                                        0.918                         0.850      0.991                 
  Li et al[@b124-ott-11-1121]                                                                                                         0.922                         0.854      0.994                 
  Akkiz et al[@b123-ott-11-1121]                                                                                                      0.923                         0.856      0.995                 
  Liu et al[@b126-ott-11-1121]                                                                                                        0.917                         0.849      0.990                 
  Kim et al[@b216-ott-11-1121]                                                                                                        0.920                         0.852      0.992                 
  Catucci et al[@b151-ott-11-1121]                                                                                                    0.916                         0.849      0.989                 
  Christensen et al[@b152-ott-11-1121]                                                                                                0.918                         0.851      0.989                 
  Mittal et al[@b156-ott-11-1121]                                                                                                     0.921                         0.854      0.993                 
  Jedlinski et al[@b155-ott-11-1121]                                                                                                  0.917                         0.850      0.989                 
  Zhan et al[@b157-ott-11-1121]                                                                                                       0.922                         0.854      0.994                 
  Zhou et al[@b158-ott-11-1121]                                                                                                       0.918                         0.850      0.990                 
  Vinci et al[@b217-ott-11-1121]                                                                                                      0.915                         0.849      0.987                 
  Hong et al[@b117-ott-11-1121]                                                                                                       0.922                         0.854      0.994                 
  George et al[@b154-ott-11-1121]                                                                                                     0.920                         0.853      0.992                 
  Linhares et al[@b160-ott-11-1121]                                                                                                   0.913                         0.847      0.985                 
  Chen et al[@b159-ott-11-1121]                                                                                                       0.916                         0.849      0.988                 
  Min et al[@b139-ott-11-1121]                                                                                                        0.918                         0.850      0.990                 
  Zhu et al[@b162-ott-11-1121]                                                                                                        0.921                         0.854      0.994                 
  Hezova et al[@b140-ott-11-1121]                                                                                                     0.915                         0.848      0.987                 
  Zhang et al[@b215-ott-11-1121]                                                                                                      0.918                         0.850      0.991                 
  Yoon et al[@b161-ott-11-1121]                                                                                                       0.920                         0.853      0.993                 
  Zhang et al[@b214-ott-11-1121]                                                                                                      0.919                         0.852      0.992                 
  Chu et al[@b202-ott-11-1121]                                                                                                        0.918                         0.851      0.991                 
  Vinci et al[@b220-ott-11-1121]                                                                                                      0.919                         0.851      0.991                 
  Ahn et al[@b218-ott-11-1121]                                                                                                        0.916                         0.850      0.988                 
  Lv et al[@b166-ott-11-1121]                                                                                                         0.905                         0.842      0.974                 
  Umar et al[@b219-ott-11-1121]                                                                                                       0.914                         0.848      0.986                 
  Wei et al[@b221-ott-11-1121]                                                                                                        0.918                         0.850      0.990                 
  Wang et al[@b168-ott-11-1121]                                                                                                       0.913                         0.846      0.985                 
  Zhang et al[@b170-ott-11-1121]                                                                                                      0.919                         0.851      0.992                 
  Han et al[@b164-ott-11-1121]                                                                                                        0.917                         0.849      0.990                 
  Pavlakis et al[@b208-ott-11-1121]                                                                                                   0.921                         0.854      0.994                 
  Tong et al[@b180-ott-11-1121]                                                                                                       0.913                         0.847      0.985                 
  Pu et al[@b199-ott-11-1121]                                                                                                         0.918                         0.851      0.990                 
  Bansal et al[@b171-ott-11-1121]                                                                                                     0.919                         0.852      0.991                 
  Kupcinskas et al[@b177-ott-11-1121]                                                                                                 0.916                         0.849      0.988                 
  Qu et al[@b179-ott-11-1121]                                                                                                         0.923                         0.855      0.995                 
  Wang et al[@b181-ott-11-1121]                                                                                                       0.916                         0.848      0.988                 
  Dikeakos et al[@b173-ott-11-1121]                                                                                                   0.931                         0.866      1.001                 
  Qi et al[@b201-ott-11-1121]                                                                                                         0.924                         0.857      0.996                 
  Chu et al[@b172-ott-11-1121]                                                                                                        0.914                         0.847      0.986                 
  Parlayan et al[@b222-ott-11-1121]                                                                                                   0.918                         0.851      0.990                 
  Li et al[@b178-ott-11-1121]                                                                                                         0.913                         0.846      0.985                 
  Du et al[@b174-ott-11-1121]                                                                                                         0.914                         0.847      0.986                 
  Omrani et al[@b200-ott-11-1121]                                                                                                     0.918                         0.851      0.989                 
  Kou et al[@b206-ott-11-1121]                                                                                                        0.921                         0.854      0.994                 
  Roy et al[@b209-ott-11-1121]                                                                                                        0.915                         0.848      0.987                 
  Li et al[@b178-ott-11-1121]                                                                                                         0.906                         0.845      0.971                 
  Deng et al[@b182-ott-11-1121]                                                                                                       0.913                         0.847      0.985                 
  Qi et al[@b187-ott-11-1121]                                                                                                         0.923                         0.856      0.995                 
  Dikaiakos et al[@b183-ott-11-1121]                                                                                                  0.914                         0.848      0.987                 
  Li et al[@b184-ott-11-1121]                                                                                                         0.911                         0.845      0.982                 
  Li et al[@b184-ott-11-1121]                                                                                                         0.922                         0.855      0.995                 
  Nikolic et al[@b186-ott-11-1121]                                                                                                    0.919                         0.852      0.991                 
  He et al[@b205-ott-11-1121]                                                                                                         0.917                         0.850      0.990                 
  Sushma et al[@b212-ott-11-1121]                                                                                                     0.921                         0.855      0.994                 
  Sodhi et al[@b210-ott-11-1121]                                                                                                      0.913                         0.847      0.984                 
  Jiang et al[@b141-ott-11-1121]                                                                                                      0.914                         0.847      0.986                 
  Toraih et al[@b213-ott-11-1121]                                                                                                     0.914                         0.848      0.986                 
  Dai et al[@b189-ott-11-1121]                                                                                                        0.922                         0.855      0.995                 
  Zhao et al[@b197-ott-11-1121]                                                                                                       0.914                         0.848      0.986                 
  Song et al[@b194-ott-11-1121]                                                                                                       0.923                         0.856      0.995                 
  Shen et al[@b193-ott-11-1121]                                                                                                       0.918                         0.849      0.992                 
  Li et al[@b190-ott-11-1121]                                                                                                         0.921                         0.854      0.993                 
  Li et al[@b191-ott-11-1121]                                                                                                         0.923                         0.856      0.995                 
  Xu et al[@b195-ott-11-1121]                                                                                                         0.922                         0.854      0.994                 
  Qiu et al[@b192-ott-11-1121]                                                                                                        0.921                         0.854      0.993                 
  Jiang et al[@b141-ott-11-1121]                                                                                                      0.921                         0.854      0.994                 
  Yin et al[@b196-ott-11-1121]                                                                                                        0.919                         0.851      0.992                 
  Zhang et al[@b214-ott-11-1121]                                                                                                      0.918                         0.851      0.991                 
  Sun et al[@b211-ott-11-1121]                                                                                                        0.919                         0.852      0.992                 
  Toraih et al[@b213-ott-11-1121]                                                                                                     0.915                         0.848      0.986                 
  Morales et al[@b207-ott-11-1121]                                                                                                    0.918                         0.851      0.991                 
  Gu et al[@b203-ott-11-1121]                                                                                                         0.911                         0.845      0.982                 
  Hashemi et al[@b204-ott-11-1121]                                                                                                    0.915                         0.848      0.986                 
  Combined[@b117-ott-11-1121]--[@b125-ott-11-1121],[@b140-ott-11-1121],[@b141-ott-11-1121],[@b150-ott-11-1121]--[@b222-ott-11-1121]   0.918                         0.851      0.989                 

###### 

*P*-values of Begg's and Egger's test for the polymorphism rs11614913

  ---------------------------------------------------------------------
  Polymorphism   Comparison   Subgroup   Begg's test\   Egger's test\
                                         (*P*\>*z*)     (*P*\>*t*)
  -------------- ------------ ---------- -------------- ---------------
  rs11614913     T vs C       Overall    0.660          0.923

  Taqman         0.368        0.723                     

  PCR            0.640        0.859                     

  Asian          0.946        0.854                     

  Caucasian      0.147        0.969                     

  HB             0.509        0.386                     

  PB             0.251        0.579                     

  TT vs CC       Overall      0.971      0.822          

  Taqman         0.719        0.606                     

  PCR            0.832        0.762                     

  Asian          0.578        0.758                     

  Caucasian      0.163        0.971                     

  HB             0.721        0.489                     

  PB             0.666        0.880                     

  TC vs CC       Overall      0.951      0.761          

  Taqman         0.418        0.289                     

  PCR            0.839        0.933                     

  Asian          0.991        0.546                     

  Caucasian      0.902        0.767                     

  HB             0.721        0.601                     

  PB             0.965        0.453                     

  TT+TC vs CC    Overall      0.592      0.401          

  Taqman         0.418        0.613                     

  PCR            0.734        0.598                     

  Asian          0.986        0.185                     

  Caucasian      0.300        0.770                     

  HB             0.737        0.543                     

  PB             0.584        0.593                     

  TT vs TC+CC    Overall      0.908      0.899          

  Taqman         0.719        0.440                     

  PCR            0.912        0.917                     

  Asian          0.795        0.688                     

  Caucasian      0.537        0.857                     

  HB             0.673        0.503                     

  PB             0.914        0.508                     
  ---------------------------------------------------------------------

**Abbreviations:** HB, hospital based; PB, population based; PCR, polymerase chain reaction.
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![The flow diagram of the included and excluded studies.](ott-11-1121Fig1){#f1-ott-11-1121}

![Forest plots of the association between miR-196a2 rs11614913 polymorphism and cancer risk in different cancer types for homozygote comparison (TT vs CC).\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** BRC, breast cancer; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HCC, hepatocellular carcinoma; HNC, head and neck cancer; LC, lung cancer; miR-196a2, microRNA-196a2; OR, odds ratio.](ott-11-1121Fig2){#f2-ott-11-1121}

![Forest plots of the association between miR-196a2 rs11614913 polymorphism and cancer risk in different cancer types for recessive model (TT vs TC+CC).\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** BRC, breast cancer; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HCC, hepatocellular carcinoma; HNC, head and neck cancer; LC, lung cancer; miR-196a2, microRNA-196a2; OR, odds ratio.](ott-11-1121Fig3){#f3-ott-11-1121}

![Begg's funnel plot for publication bias of miR-196a2 rs11614913 polymorphism and cancer risk by homozygote comparison and recessive model.\
**Notes:** Each point represents a separate study for the indicated association. LogES represents natural logarithm of OR. Horizontal line means magnitude of the effect. Funnel plot with pseudo 95% confidence limits was used.\
**Abbreviations:** miR-196a2, microRNA-196a2; OR, odds ratio.](ott-11-1121Fig4){#f4-ott-11-1121}

###### 

Characteristics of studies included in the meta-analysis

  Author                                          Year   Country     Ethnicity   Cancer type   Genotyping method   Source of control   Case   Control   HWE                         
  ----------------------------------------------- ------ ----------- ----------- ------------- ------------------- ------------------- ------ --------- ----- ----- ------- ------- -------
  Hu et al[@b7-ott-11-1121]                       2008   China       Asian       LC            PCR                 PB                  152    264       140   32    52      23      0.827
  Hu et al[@b35-ott-11-1121]                      2009   China       Asian       BRC           PCR-RFLP            PB                  287    483       239   358   517     218     0.207
  Tian et al[@b3-ott-11-1121]                     2009   China       Asian       LC            PCR-RFLP            PB                  293    512       253   307   519     209     0.700
  Hoffman et al[@b5-ott-11-1121]                  2009   USA         Caucasian   BRC           TaqMan              HB                  71     229       166   36    209     181     0.583
  Catucci et al[@b36-ott-11-1121]                 2010   Italy       Caucasian   BRC           TaqMan              PB                  244    842       776   377   1,246   1,116   0.326
  Wang et al[@b38-ott-11-1121]                    2010   China       Asian       ESCC          PCR                 PB                  48     262       148   111   250     128     0.600
  Okubo et al[@b83-ott-11-1121]                   2010   Japan       Asian       GC            Gel Pictures        HB                  166    281       105   372   592     216     0.466
  Peng et al[@b4-ott-11-1121]                     2010   China       Asian       GC            PCR-RFLP            PB                  43     94        76    50    107     56      0.936
  Srivastava et al[@b10-ott-11-1121]              2010   India       Asian       GLC           PCR-RFLP            PB                  121    97        21    121   94      15      0.566
  Dou et al[@b6-ott-11-1121]                      2010   China       Asian       Glioma        PCR-LDR             HB                  189    343       111   208   305     143     0.119
  Li et al[@b9-ott-11-1121]                       2010   China       Asian       HCC           PCR-RFLP            HB                  82     150       78    78    102     42      0.402
  Akkiz et al[@b8-ott-11-1121]                    2010   Turkey      Caucasian   HCC           PCR-RFLP            HB                  22     86        77    40    87      58      0.492
  Liu et al[@b11-ott-11-1121]                     2010   USA         Caucasian   HNC           PCR-RFLP            PB                  194    565       350   202   545     383     0.737
  Kim et al[@b110-ott-11-1121]                    2010   Korea       Asian       LC            PCR-RFLP            HB                  162    305       187   185   300     155     0.126
  Catucci et al[@b36-ott-11-1121]                 2010   Germany     Caucasian   BRC           MassARRAY           PB                  216    696       584   157   512     432     0.711
  Christensen et al[@b37-ott-11-1121]             2010   USA         Caucasian   HNC           AppliedBiosystems   PB                  0      302       182   0     367     188     NA
  Mittal et al[@b41-ott-11-1121]                  2011   India       Asian       BLC           PCR-RFLP            PB                  5      131       76    14    127     109     0.003
  Jedlinski et al[@b40-ott-11-1121]               2011   Australia   Caucasian   BRC           PCR                 PB                  33     86        68    31    82      58      0.830
  Zhan et al[@b42-ott-11-1121]                    2011   China       Asian       CRC           PCR-RFLP            HB                  56     128       68    163   267     113     0.849
  Zhou et al[@b43-ott-11-1121]                    2011   China       Asian       CSCC          PCR-RFLP            PB                  57     123       46    82    169     58      0.077
  Vinci et al[@b111-ott-11-1121]                  2011   Italy       Caucasian   LC            TaqMan              PB                  12     54        35    10    61      58      0.267
  Hong et al[@b2-ott-11-1121]                     2011   Korea       Asian       LC            TaqMan              HB                  96     224       86    134   198     96      0.163
  George et al[@b39-ott-11-1121]                  2011   Italy       Caucasian   PC            PCR-RFLP            PB                  3      101       55    10    114     106     0.002
  Linhares et al[@b45-ott-11-1121]                2012   Brazil      Mix         BRC           TaqMan              HB                  117    177       94    96    165     127     0.005
  Chen et al[@b44-ott-11-1121]                    2012   China       Asian       CRC           PCR-LDR             HB                  35     64        27    107   206     94      0.788
  Min et al[@b24-ott-11-1121]                     2012   Korea       Asian       CRC           PCR-RFLP            HB                  125    201       120   148   254     100     0.633
  Zhu et al[@b47-ott-11-1121]                     2012   China       Asian       CRC           TaqMan              HB                  130    303       140   172   295     121     0.790
  Hezova et al[@b25-ott-11-1121]                  2012   Czech       Caucasian   CRC           TaqMan              HB                  26     89        82    22    103     87      0.291
  Zhang et al[@b100-ott-11-1121]                  2012   China       Asian       CRC           PCR-RFLP            PB                  172    204       79    185   197     81      0.026
  Ahn et al[@b48-ott-11-1121]                     2013   Korea       Asian       GC            PCR-RFLP            PB                  119    242       100   128   232     87      0.322
  Yoon et al[@b46-ott-11-1121]                    2012   Korea       Asian       LC            TaqMan              PB                  99     186       101   24    32      15      0.480
  Zhang et al[@b104-ott-11-1121]                  2012   China       Asian       BRC           PCR-RFLP            PB                  133    93        17    148   89      11      0.893
  Chu et al[@b87-ott-11-1121]                     2012   China       Asian       HNC           PCR-RFLP            HB                  136    277       57    132   206     87      0.690
  Vinci et al[@b113-ott-11-1121]                  2013   Italy       Caucasian   CRC           HRMA                HB                  12     86        62    11    84      83      0.087
  Lv et al[@b51-ott-11-1121]                      2013   China       Asian       CRC           PCR-RFLP            PB                  114    223       10    91    331     109     0.000
  Umar et al[@b112-ott-11-1121]                   2013   India       Asian       ESCC          PCR-RFLP            HB                  22     121       146   16    122     171     0.330
  Wei et al[@b114-ott-11-1121]                    2013   China       Asian       ESCC          SNPscanTM           HB                  106    196       65    113   170     87      0.141
  Toraih et al[@b98-ott-11-1121]                  2016   Egypt       Caucasian   OSCC          PCR                 PB                  32     93        84    10    35      55      0.221
  Wang et al[@b53-ott-11-1121]                    2013   China       Asian       GC            TaqMan              HB                  226    371       152   232   448     220     0.898
  Zhang et al[@b55-ott-11-1121]                   2013   China       Asian       HCC           MassARRAY           HB                  294    488       214   328   502     165     0.245
  Han et al[@b49-ott-11-1121]                     2013   China       Asian       HCC           PCR                 PB                  305    505       207   304   485     220     0.310
  Tong et al[@b65-ott-11-1121]                    2013   China       Asian       ALL           TaqMan              HB                  159    308       103   237   307     129     0.434
  Pavlakis et al[@b93-ott-11-1121]                2013   Greece      Caucasian   PCC           PCR-RFLP            HB                  48     33        12    50    58      14      0.647
  Pu et al[@b84-ott-11-1121]                      2014   China       Asian       GC            PCR-RFLP            HB                  25     95        39    86    324     101     0.000
  Bansal et al[@b56-ott-11-1121]                  2014   India       Asian       BRC           PCR-RFLP            PB                  12     41        68    21    59      85      0.042
  Kupcinskas et al[@b62-ott-11-1121]              2014   Lithuania   Caucasian   CRC           PCR                 HB                  27     87        79    54    174     199     0.104
  Qu et al[@b64-ott-11-1121]                      2014   China       Asian       ESCC          PCR                 PB                  48     207       126   82    211     133     0.918
  Wang et al[@b66-ott-11-1121]                    2014   China       Asian       ESCC          PCR-LDR             PB                  162    307       128   154   298     145     0.970
  Dikeakos et al[@b58-ott-11-1121]                2014   Greece      Caucasian   GC            PCR-RFLP            HB                  15     46        102   172   229     79      0.850
  Qi et al[@b86-ott-11-1121]                      2014   China       Asian       HCC           PCR                 HB                  60     209       45    121   214     71      0.156
  Chu et al[@b57-ott-11-1121]                     2014   China       Asian       HCC           PCR-RFLP            HB                  66     81        41    100   167     70      0.986
  Parlayan et al[@b115-ott-11-1121]               2014   Japan       Asian       LC            TaqMan              HB                  38     81        29    146   270     108     0.410
  Li et al[@b63-ott-11-1121]                      2014   China       Asian       NPC           TaqMan              HB                  322    489       209   270   518     218     0.301
  Du et al[@b59-ott-11-1121],[@b60-ott-11-1121]   2014   China       Asian       RCC           PCR                 HB                  121    189       43    109   179     74      0.974
  Omrani et al[@b85-ott-11-1121]                  2014   Iran        Asian       BRC           PCR-RFLP            PB                  0      25        78    0     18      218     NA
  Kou et al[@b91-ott-11-1121]                     2014   China       Asian       HCC           PCR                 HB                  37     150       84    103   304     125     0.001
  Roy et al[@b94-ott-11-1121]                     2014   India       Asian       HNC           AppliedBiosystems   HB                  46     187       218   38    168     242     0.250
  Li et al[@b63-ott-11-1121]                      2014   China       Asian       HNC           AppliedBiosystems   PB                  322    489       209   270   518     218     0.300
  Deng et al[@b67-ott-11-1121]                    2015   China       Asian       BLC           PCR-RFLP            PB                  52     66        41    76    166     56      0.040
  Qi et al[@b72-ott-11-1121]                      2015   China       Asian       BRC           PCR                 PB                  168    119       34    185   88      17      0.141
  Dikaiakos et al[@b68-ott-11-1121]               2015   Greece      Caucasian   CRC           PCR-RFLP            PB                  69     69        19    117   149     33      0.156
  Li et al[@b69-ott-11-1121]                      2015   China       Asian       HCC           PCR                 HB                  51     131       84    30    123     113     0.689
  Li et al[@b69-ott-11-1121]                      2015   China       Asian       NHL           PCR-RFLP            PB                  111    146       61    144   134     42      0.225
  Nikolic et al[@b71-ott-11-1121]                 2015   Serbia      Caucasian   PC            PCR-RFLP            PB                  40     161       150   41    147     121     0.728
  He et al[@b90-ott-11-1121]                      2015   China       Asian       BRC           MassARRAY           HB                  134    223       93    136   233     81      0.990
  Sushma et al[@b97-ott-11-1121]                  2015   India       Asian       OSCC          PCR-RFLP            PB                  68     10        22    81    15      6       0.212
  Sodhi et al[@b95-ott-11-1121]                   2015   India       Asian       LC            PCR-RFLP            PB                  19     161       70    8     146     101     0.000
  Jiang et al[@b26-ott-11-1121]                   2016   China       Asian       GC            PCR                 HB                  300    423       166   290   487     198     0.804
  Dai et al[@b74-ott-11-1121]                     2016   China       Asian       BRC           MassARRAY           HB                  98     265       197   144   284     155     0.540
  Zhao et al[@b82-ott-11-1121]                    2016   China       Asian       BRC           TaqMan              PB                  33     50        31    25    61      28      0.449
  Song et al[@b79-ott-11-1121]                    2016   China       Asian       OC            PCR                 PB                  111    247       121   142   203     86      0.385
  Shen et al[@b78-ott-11-1121]                    2016   China       Asian       ESCC          SNaPshot            PB                  407    698       295   672   1,121   392     0.043
  Li et al[@b75-ott-11-1121]                      2016   China       Asian       GC            PCR                 HB                  75     83        24    92    79      11      0.265
  Li et al[@b76-ott-11-1121]                      2016   China       Asian       HCC           PCR                 HB                  20     64        25    35    52      18      0.861
  Xu et al[@b80-ott-11-1121]                      2016   China       Asian       HCC           PCR-RFLP            HB                  56     128       68    163   267     113     0.849
  Qiu and Liu[@b77-ott-11-1121]                   2016   China       Asian       HCC           PCR                 PB                  61     141       68    70    121     46      0.626
  Jiang et al[@b26-ott-11-1121]                   2016   China       Asian       HCC           TaqMan              PB                  159    308       103   237   307     129     0.099
  Yin et al[@b81-ott-11-1121]                     2016   China       Asian       LC            TaqMan              PB                  149    298       128   178   297     133     0.664
  Zhang et al[@b99-ott-11-1121]                   2016   China       Asian       HCC           PCR-RFLP            HB                  65     85        25    122   138     42      0.770
  Sun et al[@b96-ott-11-1121]                     2016   China       Asian       OC            PCR                 HB                  39     66        29    77    116     34      0.360
  Toraih et al[@b98-ott-11-1121]                  2016   Egypt       Caucasian   HCC           PCR                 PB                  11     31        23    17    53      80      0.082
  Morales et al[@b92-ott-11-1121]                 2016   Chile       Mix         BRC           TaqMan              HB                  57     191       192   114   351     342     0.121
  Gu and Tu[@b88-ott-11-1121]                     2016   China       Asian       GC            PCR                 HB                  51     96        39    31    98      57      0.310
  Hashemi et al[@b89-ott-11-1121]                 2016   Iran        Asian       GC            PCR-RFLP            PB                  17     88        64    12    93      77      0.021

**Abbreviations:** ALL, acute lymphoblastic leukemia; BLC, bladder cancer; BRC, breast cancer; CRC, colorectal cancer; CSCC, cervical cancer; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; GLC, gallbladder cancer; HB, hospital based; HCC, hepatocellular carcinoma; HNC, head and neck cancer; HRMA, high-resolution melting analysis; HWE, Hardy--Weinberg equilibrium of controls; LC, lung cancer; NHL, non-Hodgkin lymphoma; NPC, nasopharyngeal carcinoma; NA, not available; OC, ovarian cancer; OSCC, oral squamous cell carcinomas; PB, population based; PC, prostate cancer; PCC, pancreatic cancer; PCR, polymerase chain reaction; PCR-LDR, polymerase chain reaction-ligation detection reaction; PCR-RFLP, polymerase chain reaction restriction fragment length polymorphism; RCC, renal cell carcinoma.

###### 

Meta-analysis of miR-192a rs11614913 polymorphism with cancer risk

  rs11614913              n[a](#tfn3-ott-11-1121){ref-type="table-fn"}   Case/control    T vs C                 TT vs CC    TC vs CC                                                                                                     
  ----------------------- ---------------------------------------------- --------------- ---------------------- ----------- ---------- ------- ---------------------- ----------- ------- ------- ---------------------- ------- ------- -------
  **(A)**                                                                                                                                                                                                                                
  Total                   84                                             35,802/41,541   0.958 (0.911--1.008)   0.096       0.000      81.30   0.900 (0.813--0.987)   **0.043**   0.000   78.80   1.005 (0.935--1.079)   0.902   0.000   71.60
  **Genotyping method**                                                                                                                                                                                                                  
  PCR                     57                                             19,301/22,204   0.939 (0.871--1.012)   0.100       0.000      84.50   0.849 (0.732--0.986)   **0.032**   0.000   81.70   0.987 (0.883--1.102)   0.812   0.000   77.40
  Taqman                  16                                             8,565/10,286    1.021 (0.940--1.110)   0.618       0.000      67.40   1.059 (0.894--1.253)   0.507       0.000   65.70   1.053 (0.977--1.134)   0.174   0.410   3.70
  **Ethnicity**                                                                                                                                                                                                                          
  Asian                   64                                             28,337/31,932   0.847 (0.889--0.997)   **0.038**   0.000      77.00   0.878 (0.788--0.977)   **0.017**   0.000   76.00   1.012 (0.936--1.095)   0.759   0.000   66.90
  Caucasian               18                                             7,321/8,414     0.997 (0.842--1.181)   0.971       0.000      90.30   0.974 (0.714--1.329)   0.870       0.000   86.10   0.963 (0.785--1.180)   0.714   0.000   83.90
  **Cancer type**                                                                                                                                                                                                                        
  BRC                     14                                             7,760/8,811     0.972 (0.869--1.088)   0.626       0.000      79.70   0.972 (0.869--1.088)   0.341       0.000   72.80   0.979 (0.854--1.121)   0.754   0.001   61.50
  CRC                     10                                             2,906/4,150     1.051 (0.867--1.276)   0.611       0.000      86.50   1.051 (0.867--1.276)   0.431       0.000   87.60   1.121 (0.832--1.510)   0.454   0.000   81.10
  ESCC                    6                                              3,492/4,376     0.944 (0.816--1.091)   0.435       0.001      76.80   0.944 (0.816--1.091)   0.385       0.000   82.40   1.050 (0.878--1.255)   0.594   0.040   57.20
  GC                      10                                             3,723/5,256     0.857 (0.663--1.109)   0.241       0.000      93.80   0.857 (0.663--1.109)   0.276       0.000   91.50   0.778 (0.552--1.098)   0.153   0.000   88.70
  HCC                     14                                             4,988/5,962     0.894 (0.800--0.998)   **0.047**   0.000      72.60   0.900 (0.813--0.997)   **0.039**   0.000   70.50   0.981 (0.838--1.149)   0.816   0.005   56.30
  HNC                     5                                              3,534/3,564     1.076 (1.006--1.152)   **0.033**   0.285      20.40   1.214 (1.043--1.413)   **0.012**   0.380   2.50    1.157 (0.922--1.451)   0.209   0.003   75.00
  LC                      9                                              2,786/3,191     0.95 (0.854--1.058)    0.354       0.022      55.30   0.840 (0.734--0.961)   **0.011**   0.025   48.10   0.997 (0.889--1.118)   0.961   0.056   47.20
  **Design**                                                                                                                                                                                                                             
  PB                      42                                             20,691/21,533   0.968 (0.907--1.033)   0.324       0.000      77.20   0.899 (0.777--1.017)   0.087       0.000   74.70   1.018 (0.928--1.117)   0.703   0.000   66.60
  HB                      42                                             15,111/20,008   0.945 (0.873--1.024)   0.167       0.000      84.50   0.906 (0.813--0.997)   0.211       0.000   81.90   0.987 (0.882--1.104)   0.822   0.000   75.90

  rs11614913              n[a](#tfn3-ott-11-1121){ref-type="table-fn"}   TT vs TC+CC             TT+TC vs CC                                                           
  ----------------------- ---------------------------------------------- ----------------------- ------------- ------- ------- ----------------------- ------- ------- -------
  **(B)**                                                                                                                                                              
  Total                   84                                             0.918 (0.851--0.989)    **0.025**     0.000   75.80   0.974 (0.901--1.052)    0.498   0.000   78.40
  **Genotyping method**                                                                                                                                                
  PCR                     57                                             0.880 (0.800--0.9690)   **0.009**     0.000   73.20   0.949 (0.842--1.069)    0.386   0.000   82.80
  Taqman                  16                                             1.000 (0.858--1.166)    0.996         0.000   71.90   1.063 (0.969--1.165)    0.195   0.095   34.10
  **Ethnicity**                                                                                                                                                        
  Asian                   64                                             0.895 (0.824--0.972)    **0.008**     0.000   76.50   0.972 (0.8396--1.005)   0.493   0.000   72.90
  Caucasian               17                                             1.015 (0.820--1.256)    0.894         0.000   75.30   0.966 (0.766--1.219)    0.772   0.000   89.30
  **Cancer type**                                                                                                                                                      
  BRC                     14                                             0.943 (0.815--1.091)    0.429         0.001   64.40   0.967 (0.830--1.126)    0.663   0.000   73.30
  CRC                     10                                             1.066 (0.823--1.381)    0.628         0.000   79.00   1.130 (0.826--1.546)    0.444   0.000   84.70
  ESCC                    6                                              0.813 (0.610--1.085)    0.160         0.000   81.30   1.000 (0.822--1.216)    0.997   0.008   67.80
  GC                      10                                             0.910 (0.697--1.189)    0.489         0.000   83.90   0.763 (0.507--1.148)    0.194   0.000   92.90
  HCC                     14                                             0.800 (0.678--0.944)    **0.008**     0.000   67.40   0.919 (0.776--1.089)    0.332   0.000   66.20
  HNC                     5                                              1.205 (0.799--1.817)    0.375         0.000   90.10   1.156 (0.950--1.406)    0.148   0.011   69.10
  LC                      9                                              0.858 (0.771--0.955)    **0.005**     0.158   32.50   0.997 (0.834--1.191)    0.973   0.019   56.20
  **Design**                                                                                                                                                           
  PB                      42                                             0.924 (0.826--1.034)    0.170         0.000   78.10   0.988 (0.897--1.087)    0.800   0.000   72.40
  HB                      42                                             0.912 (0.823--1.010)    0.078         0.000   73.90   0.955 (0.843--1.081)    0.465   0.000   82.70

**Notes:** Random-effects model was used when *P*-value of *Q*-test for heterogeneity test (P--H) is \<0.05; otherwise, fixed-effect model was used. *I*^2^: 0%--25%, no heterogeneity; 25%--50%, modest heterogeneity; ≥50%, high heterogeneity.

Number of studies involved. Bold figures indicate statistically significant (*P*\<0.05).

**Abbreviations:** BRC, breast cancer; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HB, hospital based; HCC, hepatocellular carcinoma; HNC, head and neck cancer; LC, lung cancer; OR, odds ratio; PB, population based; PCR, polymerase chain reaction; P--H, *P*-value of heterogeneity test.

###### 

Methodological quality of the included studies according to the Newcastle--Ottawa scale

  Author                                          Adequacy of case definition   Representativeness of the cases   Selection of controls   Definition of controls   Comparability of cases/controls   Ascertainment of exposure   Same method of ascertainment   Non-response rate
  ----------------------------------------------- ----------------------------- --------------------------------- ----------------------- ------------------------ --------------------------------- --------------------------- ------------------------------ -------------------
  Hu et al[@b7-ott-11-1121]                       \*                            \*                                \*                      \*                       \*\*                              \*                          \*                             NA
  Hu et al[@b35-ott-11-1121]                      \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Tian et al[@b3-ott-11-1121]                     \*                            \*                                NA                      \*                       \*                                \*                          \*                             NA
  Hoffman et al[@b5-ott-11-1121]                  \*                            \*                                \*                      \*                       \*                                \*                          \*                             NA
  Catucci et al[@b36-ott-11-1121]                 \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Wang et al[@b38-ott-11-1121]                    \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Okubo et al[@b83-ott-11-1121]                   \*                            \*                                \*                      \*                       \*\*                              \*                          \*                             NA
  Peng et al[@b4-ott-11-1121]                     \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Srivastava et al[@b10-ott-11-1121]              \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Dou et al[@b6-ott-11-1121]                      \*                            \*                                NA                      NA                       \*                                NA                          \*                             NA
  Li et al[@b9-ott-11-1121]                       \*                            \*                                \*                      \*                       \*\*                              NA                          \*                             NA
  Akkiz et al[@b8-ott-11-1121]                    \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Liu et al[@b11-ott-11-1121]                     \*                            \*                                NA                      \*                       \*                                \*                          \*                             NA
  Kim et al[@b110-ott-11-1121]                    \*                            \*                                NA                      NA                       \*                                \*                          \*                             NA
  Catucci et al[@b36-ott-11-1121]                 \*                            \*                                \*                      \*                       \*\*                              \*                          \*                             NA
  Christensen et al[@b37-ott-11-1121]             \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Mittal et al[@b41-ott-11-1121]                  \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Jedlinski et al[@b40-ott-11-1121]               \*                            \*                                \*                      \*                       \*\*                              NA                          \*                             NA
  Zhan et al[@b42-ott-11-1121]                    \*                            \*                                NA                      \*                       \*                                NA                          \*                             NA
  Zhou et al[@b43-ott-11-1121]                    \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Vinci et al[@b111-ott-11-1121]                  \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Hong et al[@b2-ott-11-1121]                     \*                            \*                                NA                      \*                       \*                                \*                          \*                             NA
  George et al[@b39-ott-11-1121]                  \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Linhares et al[@b45-ott-11-1121]                \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Chen et al[@b44-ott-11-1121]                    \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Min et al[@b24-ott-11-1121]                     \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Zhu et al[@b47-ott-11-1121]                     \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Hezova et al[@b25-ott-11-1121]                  \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Zhang et al[@b100-ott-11-1121]                  \*                            \*                                \*                      \*                       \*\*                              \*                          \*                             NA
  Ahn et al[@b48-ott-11-1121]                     \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Yoon et al[@b46-ott-11-1121]                    \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Zhang et al[@b104-ott-11-1121]                  \*                            \*                                \*                      \*                       \*\*                              NA                          \*                             NA
  Chu et al[@b87-ott-11-1121]                     \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Vinci et al[@b113-ott-11-1121]                  \*                            \*                                \*                      \*                       \*\*                              NA                          \*                             NA
  Lv et al[@b51-ott-11-1121]                      \*                            \*                                \*                      \*                       \*\*                              NA                          \*                             NA
  Umar et al[@b112-ott-11-1121]                   \*                            \*                                NA                      NA                       \*\*                              \*                          \*                             NA
  Wei et al[@b114-ott-11-1121]                    \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Toraih et al[@b98-ott-11-1121]                  \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Wang et al[@b53-ott-11-1121]                    \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Zhang et al[@b55-ott-11-1121]                   \*                            \*                                NA                      NA                       \*\*                              NA                          \*                             NA
  Han et al[@b49-ott-11-1121]                     \*                            \*                                \*                      \*                       \*\*                              \*                          \*                             NA
  Tong et al[@b65-ott-11-1121]                    \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Pavlakis et al[@b93-ott-11-1121]                \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Pu et al[@b84-ott-11-1121]                      \*                            \*                                \*                      \*                       \*\*                              NA                          \*                             NA
  Bansal et al[@b56-ott-11-1121]                  \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Kupcinskas et al[@b62-ott-11-1121]              \*                            \*                                \*                      \*                       \*\*                              \*                          \*                             NA
  Qu et al[@b64-ott-11-1121]                      \*                            \*                                NA                      NA                       \*\*                              \*                          \*                             NA
  Wang et al[@b66-ott-11-1121]                    \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Dikeakos et al[@b58-ott-11-1121]                \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Qi et al[@b86-ott-11-1121]                      \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Chu et al[@b57-ott-11-1121]                     \*                            \*                                \*                      \*                       \*                                \*                          \*                             NA
  Parlayan et al[@b115-ott-11-1121]               \*                            \*                                \*                      \*                       \*\*                              \*                          \*                             NA
  Li et al[@b63-ott-11-1121]                      \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Du et al[@b59-ott-11-1121],[@b60-ott-11-1121]   \*                            \*                                NA                      \*                       \*                                NA                          \*                             NA
  Omrani et al[@b85-ott-11-1121]                  \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Kou et al[@b91-ott-11-1121]                     \*                            \*                                \*                      \*                       \*\*                              \*                          \*                             NA
  Roy et al[@b94-ott-11-1121]                     \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Li et al[@b63-ott-11-1121]                      \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Deng et al[@b67-ott-11-1121]                    \*                            \*                                \*                      \*                       \*\*                              NA                          \*                             NA
  Qi et al[@b72-ott-11-1121]                      \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Dikaiakos et al[@b68-ott-11-1121]               \*                            \*                                \*                      \*                       \*                                \*                          \*                             NA
  Li et al[@b69-ott-11-1121]                      \*                            \*                                NA                      NA                       \*\*                              \*                          \*                             NA
  Li et al[@b69-ott-11-1121]                      \*                            \*                                NA                      NA                       \*\*                              \*                          \*                             NA
  Nikolic et al[@b71-ott-11-1121]                 \*                            \*                                \*                      \*                       \*\*                              \*                          \*                             NA
  He et al[@b90-ott-11-1121]                      \*                            \*                                NA                      NA                       \*\*                              NA                          \*                             NA
  Sushma et al[@b97-ott-11-1121]                  \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Sodhi et al[@b95-ott-11-1121]                   \*                            \*                                \*                      \*                       \*\*                              \*                          \*                             NA
  Jiang et al[@b26-ott-11-1121]                   \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Dai et al[@b74-ott-11-1121]                     \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Zhao et al[@b82-ott-11-1121]                    \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Song et al[@b79-ott-11-1121]                    \*                            \*                                \*                      \*                       \*                                NA                          \*                             NA
  Shen et al[@b78-ott-11-1121]                    \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Li et al[@b75-ott-11-1121]                      \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Li et al[@b76-ott-11-1121]                      \*                            \*                                NA                      \*                       \*                                \*                          \*                             NA
  Xu et al[@b80-ott-11-1121]                      \*                            \*                                NA                      NA                       \*                                \*                          \*                             NA
  Qiu and Liu[@b77-ott-11-1121]                   \*                            \*                                \*                      \*                       \*                                \*                          \*                             NA
  Jiang et al[@b26-ott-11-1121]                   \*                            \*                                \*                      \*                       \*\*                              \*                          \*                             NA
  Yin et al[@b81-ott-11-1121]                     \*                            \*                                NA                      \*                       \*                                \*                          \*                             NA
  Zhang et al[@b99-ott-11-1121]                   \*                            \*                                \*                      \*                       \*\*                              NA                          \*                             NA
  Sun et al[@b96-ott-11-1121]                     \*                            \*                                \*                      \*                       \*                                \*                          \*                             NA
  Toraih et al[@b98-ott-11-1121]                  \*                            \*                                NA                      \*                       \*\*                              NA                          \*                             NA
  Morales et al[@b92-ott-11-1121]                 \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA
  Gu and Tu[@b88-ott-11-1121]                     \*                            \*                                NA                      \*                       \*                                \*                          \*                             NA
  Hashemi et al[@b89-ott-11-1121]                 \*                            \*                                NA                      \*                       \*\*                              \*                          \*                             NA

**Notes:** This table identified "high"quality choices with a "\*". A study can be awarded a maximum of one "\*" for each numbered item within the selection and exposure categories. A maximum of two "\*\*" can be given for comparability.

**Abbreviation:** NA, not available.

[^1]: These authors contributed equally to this work
